BioCryst Pharmaceuticals, Inc.
BCRX
$6.82
$0.416.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.83% | 34.98% | 32.54% | 34.87% | 17.42% |
| Total Other Revenue | -- | -- | -- | -- | -71.42% |
| Total Revenue | 40.83% | 34.98% | 32.54% | 34.87% | 17.42% |
| Cost of Revenue | -17.20% | -7.72% | -24.60% | -2.92% | -11.34% |
| Gross Profit | 188.98% | 87.92% | 130.99% | 130.70% | 584.17% |
| SG&A Expenses | 25.68% | 28.50% | 20.03% | 24.02% | 27.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.74% | 10.88% | -2.54% | 10.35% | 4.20% |
| Operating Income | 88.06% | 164.52% | 142.32% | 49.01% | 18.50% |
| Income Before Tax | 58.85% | 62.46% | 83.24% | 33.51% | 11.62% |
| Income Tax Expenses | 156.18% | 77.58% | -76.76% | -45.60% | -1,982.89% |
| Earnings from Continuing Operations | 56.59% | 61.18% | 83.17% | 33.66% | 13.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.59% | 61.18% | 83.17% | 33.66% | 13.71% |
| EBIT | 88.06% | 164.52% | 142.32% | 49.01% | 18.50% |
| EBITDA | 93.26% | 169.59% | 144.74% | 49.37% | 19.94% |
| EPS Basic | 57.85% | 64.43% | 84.58% | 39.31% | 19.91% |
| Normalized Basic EPS | 56.67% | 65.59% | 74.83% | 39.18% | 24.39% |
| EPS Diluted | 58.02% | 64.43% | 84.65% | 39.31% | 19.57% |
| Normalized Diluted EPS | 56.67% | 65.59% | 74.83% | 39.18% | 24.39% |
| Average Basic Shares Outstanding | 2.97% | 9.10% | 9.15% | 9.31% | 7.75% |
| Average Diluted Shares Outstanding | 2.97% | 9.10% | 9.15% | 9.31% | 7.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
